Circio Holding ASA (CRNA) - tidl: Targovax (TRVX) 1

[Bompiole]

Oppgang,berre ei dobling no så e eg på snitt

[anon79663630]

Nå må dere jobbe på gutter. Øverst på prioriteringslista dette - alpha-1 antitrypsin deficiency (AATD).

Sanofi signs agreement to acquire Inhibrx for $1.7bn

[Bompiole]

Ja tenk om

[anon79663630]

Når selskapet har sagt klinikk innen 3 år, er det samtidig sagt noe om innen hvilket område ? Kan ikke huske at det er nevnt ?

[anon79663630]

Må i så fall være EDW. Så uflidd ut på Redeye.

[anon79663630]

Her er presentasjonen fra Redeye. Tror ikke den er lagt ut tidligere ?

Circio: CEO Erik Digman Wiklund presents at Redeye Fight Cancer Event 2024 – January 24

[Xon]

[Celestar]

Omsetning på 94k sier vel litt om interessen. Var 1000 aksjer i sluttauksjonen som sikret grønt.

[TekBot]

The first patient has been dosed in Circio’s TG01 triple combination study

· The first enrolled patient was dosed on 31 January in Washington, D.C., USA
· In this phase 2 study, the TG01 mutant RAS cancer vaccine is being tested in
combination with daratumumab (Janssen) and nivolumab (BMS)
…

Vis børsmeldingen

· This is the first time TG01 is tested in non-small cell lung cancer (NSCLC)

Oslo, Norway, 1 February 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA and immunotherapy medicines, today
announces that the first patient has been dosed in the collaborative phase 2
trial sponsored by Georgetown University. In this study, mutant RAS cancer
vaccine TG01 is being tested in combination with daratumumab (anti-CD38,
Janssen) and nivolumab (anti-PD1, BMS) in patients with RAS-mutated pancreatic
cancer (PDAC) and patients with non-small cell lung cancer (NSCLC).

Mutations in the RAS-family of genes are a major cause of cancer and found in
over 90% of PDAC and 30% of NSCLC cancer patients. RAS-mutated cancers typically
have poor prognosis with few targeted treatment alternatives, and the medical
need for novel therapeutic options remains high.

To further study this unmet medical need, a phase 2 trial has been initiated to
test the combination of daratumumab (Janssen), nivolumab (BMS) and TG01 in
advanced PDAC and anti-PD1 resistant NSCLC (see announcement Nov 16
2023 (https://www.circio.com/en/circio-joins-collaboration-to-test-the
-combination-of-tg01-vaccination-with-daratumumab-and-nivolumab-in-immunotherapy
-resistant-patients-with-mutant-ras-cancers/)). The study will enroll 54 KRAS
-mutated patients in total, 27 immunotherapy-naïve PDAC patients and 27 NSCLC
patients who have progressed on prior anti-PD1 therapy.

Ola Melin, Head of the TG program at Circio, said: “The externally sponsored
clinical program with our enhanced TG01 cancer vaccine is progressing well. The
Georgetown study is now the third active clinical trial with patients on
treatment, and comes in addition to the multiple myeloma study at Oslo
University Hospital and the pancreatic cancer study at Kansas University.
Collaborations are the core of the TG01 development strategy, and we are
continuing to execute on the plan to advance our KRAS program through external
development in multiple settings and geographies.”

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for rare disease, vaccines, and cancer. The proprietary
circVec technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA from DNA and viral vectors, which can be
deployed for many purposes. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.

Kilde

[bowie]

Atlas som holder oss ned, men også flytende ?

[lasseht]

Denne aksjen er å blir sittende i hengemyra,andre selskap som får nyheter stiger bra. denne går alltid i rødt​:face_vomiting:

[Frs2904]

Virker som at rekrutteringen til TG-studiene går på skinner og da tenker jeg at vi har spennende data foran oss. Paradoksalt nok, kan vi ende med at CRNA feiler og blir en flopp og at vi da er tilbake til utgangspunktet TG. Mye kommer til å være avklart i løpet av 7-8 måneder.

[larslars]

Jeg har slutta å betale for Piratos analyser men noen syns jo at all oppmerksomhet er god oppmerksomhet:

https://twitter.com/ParetoSecNO/status/1752997177335378121

[Pk2k]

Bgbio og Circio, to kvalitets selskaper

[anon79663630]

54 foran i køen for review av IND hos NMPA i Kina pr i dag.

[Bompiole]

no da?

[anon79663630]

Natta der nå

[anon79663630]

Faktisk rykka bakover i køen nå. Han som stod med søknaden i hånda måtte ut for å pisse.

[Bompiole]

ikkje bra,men rekner med E.W og L.G tat affære og fikser biffen.Dei er vel lei av å miste 20% av lønna

[lasseht]

dem burde vel ikke hatt mer enn 20% av lønna dem har i dag.